Free Trial
OTCMKTS:BSEM

BioStem Technologies (BSEM) Stock Price, News & Analysis

BioStem Technologies logo
$12.09 -0.54 (-4.28%)
As of 05/14/2025 03:58 PM Eastern

About BioStem Technologies Stock (OTCMKTS:BSEM)

Key Stats

Today's Range
$11.75
$12.58
50-Day Range
$7.58
$15.30
52-Week Range
$6.77
$28.26
Volume
74,543 shs
Average Volume
68,824 shs
Market Capitalization
$201.94 million
P/E Ratio
17.78
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.

Receive BSEM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioStem Technologies and its competitors with MarketBeat's FREE daily newsletter.

BSEM Stock News Headlines

BSEM Expands Margins and Grows Business
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
BSEM Posts Record Revenue and Profit
See More Headlines

BSEM Stock Analysis - Frequently Asked Questions

BioStem Technologies' stock was trading at $13.84 at the start of the year. Since then, BSEM stock has decreased by 12.6% and is now trading at $12.09.
View the best growth stocks for 2025 here
.

BioStem Technologies, Inc. (OTCMKTS:BSEM) announced its quarterly earnings results on Monday, May, 12th. The company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $1.25 by $1.08. The business had revenue of $72.53 million for the quarter, compared to the consensus estimate of $101.20 million.
Read the conference call transcript
.

Shares of BSEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that BioStem Technologies investors own include NVIDIA (NVDA), Tesla (TSLA), Broadcom (AVGO), Advanced Micro Devices (AMD), SoFi Technologies (SOFI) and Energy Transfer (ET).

Company Calendar

Last Earnings
5/12/2025
Today
5/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
N/A
Sub-Industry
N/A
Current Symbol
OTCMKTS:BSEM
Previous Symbol
OTCMKTS:BSEM
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
17.78
Forward P/E Ratio
8.57
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$16.68 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$201.94 million
Optionable
N/A
Beta
-0.10
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (OTCMKTS:BSEM) was last updated on 5/15/2025 by MarketBeat.com Staff
From Our Partners